Jeito holds $1.2B close for biopharma fund as industry braces for next patent cliff [Yahoo! Finance]
JOHNSON MATTHEY S/ADR (JMPLY)
NASDAQ:AMEX Investor Relations:
matthey.com/investor
Company Research
Source: Yahoo! Finance
Pharma's $180 billion patent cliff will create more attractive opportunities in the space. Jeito II beat its target and is almost double the size of its predecessor, which closed on $630 million in 2021. Fund II also has a higher average ticket size of €150 million (about $175.7 million) and is aiming to back 15 to 20 companies. Sign up for The Europe Pitch Get our daily digest of private capital markets in the EMEA region. Subscribe The fund invests in clinical-stage biopharma companies that develop therapies for severe diseases with high unmet medical needs. It invests primarily in Europe and has already deployed in therapeutic areas including obesity, reproductive medicine, oncology, autoimmune and inflammatory diseases, neurology and cardio-metabolic diseases. With the new fund, Jeito Capital now manages €1.6 billion in assets. The biopharma industry is bracing for a period of strong M&A ahead of the next patent cliff by 2030, which puts $180 billion of pharma compan
Show less
Read more
Impact Snapshot
Event Time:
JMPLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JMPLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JMPLY alerts
High impacting JOHNSON MATTHEY S/ADR news events
Weekly update
A roundup of the hottest topics
JMPLY
News
- JMPLY vs. AIQUY: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Ruthenium prices hit record high as AI boom squeezes supply [Yahoo! Finance]Yahoo! Finance
- Honeywell cuts Johnson Matthey deal price to £1.325B; sets new 2026 closing window [Seeking Alpha]Seeking Alpha
- Honeywell may walk away from Johnson Matthey catalyst deal, Bloomberg reports [Yahoo! Finance]Yahoo! Finance
- Washcoat Composition And Coating Techniques Patent Landscape Report 2025: Analysis of 1,761 Patents Filed from Johnson Matthey, BASF, Toyota, Umicore, N E Chemcat, Cataler, GM, Honda [Yahoo! Finance]Yahoo! Finance